25 / 60
HIPERTENSIÓN / 2014 / VOL. 19
23
Bibliografía
1.
Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinology and metabolism clinics of North America. 2003;32:895-914
2.
Dufour DL, Sauther ML. Comparative and evolutionary dimensions of the energetics of human pregnancy and lactation. Am J Hum Biol. 2002;14:584-602
3.
Thatcher S, Yiannikouris F, Gupte M, et al. The adipose renin angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302:111–117.
4.
Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in
diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012 May;59(5):1069-78
5.
Baudrand R, Carvajal CA, Riquelme A, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated
with metabolic disorders in morbidly obese patients. Obes Surg. 2010 Jan;20(1):77-83.
6.
Morgan SA, McCabe EL, Gathercole LL, et al. 11-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad
Sci U S A. 2014 Jun 17;111(24)
7.
Baudrand R, Campino C, Carvajal CA, et al. Increased urinary glucocorticoid metabolites are associated with metabolic syndrome, hypoadiponectinemia,
insulin resistance and cell dysfunction. Steroids. 2011 Dec 20;76(14):1575-81
8.
Bauman DR, Whitehead A, Contino LC, et al. Evaluation of selective inhibitors of 11-HSD1 for the treatment of hypertension. Bioorg Med Chem Lett. 2013
Jun 15;23(12):3650-3
9.
Starker LF, Kunstmann JW, Carling T. Subclinical Cushing Syndrome: A Review. Surg Clin N Am. 2014; 94:657–668
10.
Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with
adrenal incidentalomas and subclinical Cushing’s syndrome. Surgery. 2012;152(6):991-997
11. Tuna MM, Imga NN, Do an BA, et al. Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of aterosclerosis.
J Endocrinol Invest. 2014; Jun 2013 [Epub ahead of print]
12. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict
major metabolic and cardiovascular outcomes: a large cross-sectional study. European Journal of Endocrinology. 2012; 166:69-677
13.
Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological
studies. Eur J Endocrinol 2012; 167:7 – 15
14. Oki K, Plonczynski MW, Luis Lam M, et al. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology
2012; 153:1774 – 1782
15. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. Eur J Endocrinol 2013; 168:R85 – R93
16.
Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013;
45:1055–1060
17. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism.
Nat Genet 2013; 45:1050 – 1054.
18. Menegaux F, Chéreau N, Peix JL, et al. Management of adrenal incidentaloma. Journal of Visceral Surgery. 2014; Aug 12. Epub ahead of print.
Conclusiones:
En los últimos años nuevas técnicas han permitido identificar mecanismos endocrinos y genéticos
implicados en la regulación de aldosterona y cortisol que tienen un rol importante en la hipertensión
arterial, tanto la asociada a la obesidad como aquella en el contexto de tumores suprarrenales.
Estos hallazgos recientes ofrecen potenciales sitios de acción específicos que pueden facilitar un
tratamiento personalizado.